Voxel-based whole-lesion enhancement parameters: a study of its clinical value in differentiating clear cell renal cell carcinoma from renal oncocytoma

被引:26
作者
Chen, Frank [1 ]
Gulati, Mittul [1 ]
Hwang, Darryl [1 ]
Cen, Steven [1 ]
Yap, Felix [1 ]
Ugwueze, Chidubem [1 ]
Varghese, Bino [1 ]
Desai, Mihir [1 ]
Aron, Manju [1 ]
Gill, Inderbir [1 ]
Duddalwar, Vinay [1 ]
机构
[1] Univ Southern Calif, Keck Sch Med, 1500 San Pablo St,2nd Floor Imaging, Los Angeles, CA 90033 USA
关键词
Clear cell renal cell carcinoma; Oncocytoma; CT; Whole-lesion enhancement; Histogram distribution; COMPUTED-TOMOGRAPHY; DIAGNOSTIC-ACCURACY; HISTOGRAM ANALYSIS; MULTIDETECTOR CT; NATURAL-HISTORY; BIPHASIC MDCT; CORE BIOPSY; MASSES; INVERSION; TUMORS;
D O I
10.1007/s00261-016-0891-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In this IRB-approved retrospective study, the surgical database was queried to derive a cohort of 94 postnephrectomy patients with ccRCC or oncocytoma (68 ccRCC, 26 oncocytoma), who underwent preoperative multiphase contrast-enhanced computed tomography (CECT) between June 2009 and August 2013. CT acquisitions were transferred to a three-dimensional workstation, and WL ROIs were manually segmented. WL enhancement and histogram distribution parameters skewness, kurtosis, standard deviation (SD), and interquartile range (IQR) were calculated. WL enhancement parameters were compared to single ROI-based enhancement using receiver operating characteristic (ROC) analysis. Oncocytoma had significantly higher WL enhancement than ccRCC in nephrographic (mean, p = 0.02; median, p = 0.03) and excretory phases (mean, p = 0.03; median p < 0.01). ccRCC had significantly higher kurtosis than oncocytoma in corticomedullary (p = 0.03) and excretory phases (p < 0.01), and significantly higher SD and IQR than oncocytoma in all postcontrast phases: corticomedullary (SD, p = 0.02; IQR, p < 0.01), nephrographic (SD, p = 0.01; IQR, p = 0.03), and excretory (SD, p < 0.01; IQR, p < 0.01). When compared to single ROI-based enhancement, WL enhancement alone did not demonstrate a statistical advantage in discriminating between ccRCC and oncocytoma (area under ROC curve of 0.78 and 0.72 respectively), but when combined with histogram distribution parameters (area under ROC curve of 0.86), it did demonstrate a slight improvement. Our study suggests that voxel-based WL enhancement parameters provide only a slight improvement over single ROI-based enhancement techniques in differentiating between ccRCC and renal oncocytoma.
引用
收藏
页码:552 / 560
页数:9
相关论文
共 50 条
  • [41] Radiogenomics Pilot Study: Association Between Radiomics and Single Nucleotide Polymorphism-Based Microarray Copy Number Variation in Diagnosing Renal Oncocytoma and Chromophobe Renal Cell Carcinoma
    Alhussaini, Abeer J.
    Veluchamy, Abirami
    Jawli, Adel
    Kernohan, Neil
    Tang, Benjie
    Palmer, Colin N. A.
    Steele, J. Douglas
    Nabi, Ghulam
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [42] Liq_ccRCC: Identification of Clear Cell Renal Cell Carcinoma Based on the Integration of Clinical Liquid Indices
    Zhao, Jianhong
    Wu, Jiangpeng
    Wei, Jinyan
    Su, Xiaolu
    Chai, Yanjun
    Li, Shuyan
    Wang, Zhiping
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [43] The prognostic value of miR-487a in clear cell renal cell carcinoma and its influence on cell biological behavior
    Liu, Shuzhen
    Zhao, Yuling
    Zhao, Yubin
    Tang, Xiaochun
    ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (04): : 346 - 353
  • [44] Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis
    Hui-Ming Jiang
    Jin-Huan Wei
    Zhi-Ling Zhang
    Yong Fang
    Bang-Fen Zhou
    Zhen-Hua Chen
    Jun Lu
    Bing Liao
    Fang-Jian Zhou
    Jun-Hang Luo
    Wei Chen
    International Urology and Nephrology, 2016, 48 : 191 - 199
  • [45] Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis
    Jiang, Hui-Ming
    Wei, Jin-Huan
    Zhang, Zhi-Ling
    Fang, Yong
    Zhou, Bang-Fen
    Chen, Zhen-Hua
    Lu, Jun
    Liao, Bing
    Zhou, Fang-Jian
    Luo, Jun-Hang
    Chen, Wei
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (02) : 191 - 199
  • [46] Differentiation of Small Clear Renal Cell Carcinoma and Oncocytoma through Magnetic Resonance Imaging-Based Radiomics Analysis: Toward the End of Percutaneous Biopsy
    Toffoli, Thibault
    Saut, Olivier
    Etchegaray, Christele
    Jambon, Eva
    Le Bras, Yann
    Grenier, Nicolas
    Marcelin, Clement
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (10):
  • [47] The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics - An immunohistochemical study with comparison to renal cell carcinoma marker
    Gokden, Neriman
    Gokden, Murat
    Phan, Dan C.
    MeKenney, Jesse K.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (10) : 1462 - 1467
  • [48] Expression of PGAM1 in renal clear cell carcinoma and its clinical significance
    Li, Chunjing
    Shu, Fangpeng
    Lei, Bin
    Lv, Daojun
    Zhang, Shoubo
    Mao, Xiangming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (08): : 9410 - 9415
  • [49] Loss of ACOX1 in clear cell renal cell carcinoma and its correlation with clinical features
    Mo, Yingxi
    Zhao, Jun
    Zhao, Ran
    Huang, Yiying
    Liang, Ziyuan
    Zhou, Xiaoying
    Chu, Jiemei
    Pan, Xinli
    Duan, Siyu
    Chen, Shiman
    Mo, Liufang
    Huang, Bizhou
    Huang, Zhaozhang
    Wei, Jiale
    Zheng, Qian
    Luo, Wenqi
    OPEN LIFE SCIENCES, 2023, 18 (01):
  • [50] Prognostic Value and Clinical Significance of Vesicular Transport-Related Genes in Clear Cell Renal Cell Carcinoma
    Ye, Dayong
    Luo, Jingxian
    Wang, Yujie
    Su, Mingqiang
    Zhang, Dayong
    Han, Dengjun
    KIDNEY & BLOOD PRESSURE RESEARCH, 2024, 49 (01) : 410 - 429